Story perspectives

China Drives Pharma Innovation Amid Patent Challenges

2/13/2026

Summary

Story summary

China has become a vital source of innovation and a strategic market for pharmaceutical firms.
Executives emphasize effective pricing strategies amid potential patent expirations.
Novartis and AstraZeneca project significant revenue growth despite patent challenges.
The direct-to-consumer obesity-drug market is expanding as Novo Nordisk and Eli Lilly face rising competition.
Mergers and acquisitions are gaining traction, with China a key focus for securing innovative assets.

1 of 1

Story summary

China has become a vital source of innovation and a strategic market for pharmaceutical firms.
Executives emphasize effective pricing strategies amid potential patent expirations.
Novartis and AstraZeneca project significant revenue growth despite patent challenges.
The direct-to-consumer obesity-drug market is expanding as Novo Nordisk and Eli Lilly face rising competition.
Mergers and acquisitions are gaining traction, with China a key focus for securing innovative assets.